Postherpetic Neuralgia-Pipeline Review, H2 2015

Postherpetic Neuralgia-Pipeline Review, H2 2015


  • Products Id :- GMDHC7240IDB
  • |
  • Pages: 102
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Postherpetic Neuralgia-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Postherpetic Neuralgia-Pipeline Review, H2 2015', provides an overview of the Postherpetic Neuralgia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Postherpetic Neuralgia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Postherpetic Neuralgia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Postherpetic Neuralgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Postherpetic Neuralgia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Postherpetic Neuralgia Overview 9

Therapeutics Development 10

Pipeline Products for Postherpetic Neuralgia-Overview 10

Pipeline Products for Postherpetic Neuralgia-Comparative Analysis 11

Postherpetic Neuralgia-Therapeutics under Development by Companies 12

Postherpetic Neuralgia-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Postherpetic Neuralgia-Products under Development by Companies 19

Postherpetic Neuralgia-Companies Involved in Therapeutics Development 21

Aestus Therapeutics, Inc. 21

Allergan Plc 22

Astellas Pharma Inc. 23

Daewoong Pharmaceutical Co., Ltd. 24

Daiichi Sankyo Company, Limited 25

Immune Pharmaceuticals Inc. 26

Merck & Co., Inc. 27

Nuvo Research Inc. 28

Pfizer Inc. 29

Phosphagenics Limited 30

Purdue Pharma L.P. 31

Relmada Therapeutics, Inc. 32

Scilex Pharmaceuticals, Inc. 33

Teva Pharmaceutical Industries Limited 34

Winston Pharmaceuticals, Inc. 35

Postherpetic Neuralgia-Therapeutics Assessment 36

Assessment by Monotherapy Products 36

Assessment by Combination Products 37

Assessment by Target 38

Assessment by Mechanism of Action 40

Assessment by Route of Administration 42

Assessment by Molecule Type 44

Drug Profiles 46

(amitriptyline + ketamine hydrochloride)-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

(naltrexone hydrochloride+ clonidine hydrochloride)-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

ASP-8477-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

ATX-08001-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

bupivacaine hydrochloride-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

C-746-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

CNV-2197944-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

DWP-05195-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Flexicaine-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

funapide-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

FV-100-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

ketoprofen-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

lidocaine hydrochloride-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

lidocaine hydrochloride patch-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

mepivacaine hydrochloride-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

mirogabalin besylate-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

MK-8291-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

NXN-462-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

oxycodone ER-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

pregabalin CR-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

senrebotase-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

V-116517-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

zucapsaicin-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Postherpetic Neuralgia-Recent Pipeline Updates 76

Postherpetic Neuralgia-Dormant Projects 89

Postherpetic Neuralgia-Discontinued Products 92

Postherpetic Neuralgia-Product Development Milestones 94

Featured News & Press Releases 94

Sep 16, 2015: FDA Accepts SCILEX Pharmaceuticals' NDA Filing for ZTlido 94

Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial 94

Apr 02, 2015: Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia 94

Feb 20, 2015: ContraVir Pharmaceuticals Provides Clinical Update on FV-100 95

Feb 19, 2015: Xenon Pharmaceuticals Partner Teva to Initiate Phase 2b Clinical Trial of TV-45070 in Post-Herpetic Neuralgia 96

Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin 97

Jan 07, 2015: ContraVir Pharmaceuticals Granted FDA Meeting to Discuss Proposal for Phase 3 Trial of FV-100 98

Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia 98

Aug 11, 2014: Scilex Pharmaceuticals Completes Trial Enrollment for Ztlido 99

Jul 14, 2014: SCILEX Pharmaceuticals Commences Dermal Safety Studies of Ztlido 100

Appendix 101

Methodology 101

Coverage 101

Secondary Research 101

Primary Research 101

Expert Panel Validation 101

Contact Us 101

Disclaimer 102

List of Tables

Number of Products under Development for Postherpetic Neuralgia, H2 2015 10

Number of Products under Development for Postherpetic Neuralgia-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Number of Products under Development by Companies, H2 2015 (Contd...1) 14

Comparative Analysis by Late Stage Development, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Development, H2 2015 17

Comparative Analysis by Unknown Stage Development, H2 2015 18

Products under Development by Companies, H2 2015 19

Products under Development by Companies, H2 2015 (Contd...1) 20

Postherpetic Neuralgia-Pipeline by Aestus Therapeutics, Inc., H2 2015 21

Postherpetic Neuralgia-Pipeline by Allergan Plc, H2 2015 22

Postherpetic Neuralgia-Pipeline by Astellas Pharma Inc., H2 2015 23

Postherpetic Neuralgia-Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015 24

Postherpetic Neuralgia-Pipeline by Daiichi Sankyo Company, Limited, H2 2015 25

Postherpetic Neuralgia-Pipeline by Immune Pharmaceuticals Inc., H2 2015 26

Postherpetic Neuralgia-Pipeline by Merck & Co., Inc., H2 2015 27

Postherpetic Neuralgia-Pipeline by Nuvo Research Inc., H2 2015 28

Postherpetic Neuralgia-Pipeline by Pfizer Inc., H2 2015 29

Postherpetic Neuralgia-Pipeline by Phosphagenics Limited, H2 2015 30

Postherpetic Neuralgia-Pipeline by Purdue Pharma L.P., H2 2015 31

Postherpetic Neuralgia-Pipeline by Relmada Therapeutics, Inc., H2 2015 32

Postherpetic Neuralgia-Pipeline by Scilex Pharmaceuticals, Inc., H2 2015 33

Postherpetic Neuralgia-Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 34

Postherpetic Neuralgia-Pipeline by Winston Pharmaceuticals, Inc., H2 2015 35

Assessment by Monotherapy Products, H2 2015 36

Assessment by Combination Products, H2 2015 37

Number of Products by Stage and Target, H2 2015 39

Number of Products by Stage and Mechanism of Action, H2 2015 41

Number of Products by Stage and Route of Administration, H2 2015 43

Number of Products by Stage and Molecule Type, H2 2015 45

Postherpetic Neuralgia Therapeutics-Recent Pipeline Updates, H2 2015 76

Postherpetic Neuralgia-Dormant Projects, H2 2015 89

Postherpetic Neuralgia-Dormant Projects (Contd..1), H2 2015 90

Postherpetic Neuralgia-Dormant Projects (Contd..2), H2 2015 91

Postherpetic Neuralgia-Discontinued Products, H2 2015 92

Postherpetic Neuralgia-Discontinued Products (Contd..1), H2 2015 93

List of Figures

Number of Products under Development for Postherpetic Neuralgia, H2 2015 10

Number of Products under Development by Companies, H2 2015 12

Comparative Analysis by Late Stage Development, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Assessment by Monotherapy Products, H2 2015 36

Assessment by Combination Products, H2 2015 37

Number of Products by Top 10 Targets, H2 2015 38

Number of Products by Stage and Top 10 Targets, H2 2015 38

Number of Products by Top 10 Mechanism of Actions, H2 2015 40

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 40

Number of Products by Routes of Administration, H2 2015 42

Number of Products by Stage and Routes of Administration, H2 2015 42

Number of Products by Molecule Types, H2 2015 44

Number of Products by Stage and Molecule Types, H2 2015 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aestus Therapeutics, Inc.

Allergan Plc

Astellas Pharma Inc.

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Immune Pharmaceuticals Inc.

Merck & Co., Inc.

Nuvo Research Inc.

Pfizer Inc.

Phosphagenics Limited

Purdue Pharma L.P.

Relmada Therapeutics, Inc.

Scilex Pharmaceuticals, Inc.

Teva Pharmaceutical Industries Limited

Winston Pharmaceuticals, Inc.

Postherpetic Neuralgia Therapeutic Products under Development, Key Players in Postherpetic Neuralgia Therapeutics, Postherpetic Neuralgia Pipeline Overview, Postherpetic Neuralgia Pipeline, Postherpetic Neuralgia Pipeline Assessment

select a license

Single User License
USD 2000 INR 129520
Site License
USD 4000 INR 259040
Corporate User License
USD 6000 INR 388560

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com